Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Post Q1 2025 Earnings of ($0.16) Per Share, Zacks Research Forecasts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Stock analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Tuesday, October 8th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings per share of ($0.16) for the quarter, down from their prior forecast of ($0.15). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.04) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q2 2025 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.25) EPS and FY2026 earnings at ($0.02) EPS.

A number of other equities research analysts also recently issued reports on the stock. Bank of America downgraded shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $2.90 to $2.50 in a research report on Thursday, June 20th. StockNews.com upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, October 5th. Needham & Company LLC decreased their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Esperion Therapeutics presently has a consensus rating of “Hold” and an average target price of $8.17.

Esperion Therapeutics Trading Down 2.1 %

NASDAQ ESPR opened at $1.89 on Friday. The company has a fifty day moving average price of $1.82 and a 200-day moving average price of $2.19. Esperion Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million.

Institutional Investors Weigh In On Esperion Therapeutics

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in Esperion Therapeutics by 71.8% during the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after purchasing an additional 3,688,796 shares during the period. Bellevue Group AG grew its stake in shares of Esperion Therapeutics by 136.5% during the 1st quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after acquiring an additional 5,739,800 shares during the period. SG Americas Securities LLC purchased a new stake in Esperion Therapeutics in the 1st quarter worth about $69,000. Marshall Wace LLP increased its holdings in Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after acquiring an additional 2,087,635 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Esperion Therapeutics by 3,278.3% during the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after purchasing an additional 555,382 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.